Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 9/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.34 |
| ▸ | RORC | P51449 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8251813 | 0.88 | NPC1 (0.38) | KCNK3NPC1RAB9ARORCLMNA | |
| SCHEMBL2097455 | 0.88 | NPC1 (0.38) | KCNK3NPC1RAB9ARORCLMNA | |
| SCHEMBL2054772 | 0.88 | NPC1 (0.37) | KCNK3NPC1RAB9ARORCLMNA | |
| SCHEMBL2054779 | 0.88 | KCNK3 (0.39) | KCNK3NPC1RAB9ARORCLMNA | |
| SCHEMBL2054776 | 0.88 | NPC1 (0.38) | KCNK3NPC1RAB9ARORCLMNA | |
| SCHEMBL4722312 | 0.78 | HDAC4 (0.42) | KCNK3HDAC4HDAC6NPC1RAB9A | |
| SCHEMBL2054775 | 0.73 | NPC1 (0.42) | KCNK3NPC1RAB9ALMNA | |
| SCHEMBL2054774 | 0.69 | RORC (0.32) | RORC | |
| SCHEMBL4722308 | 0.69 | SLC6A9 (0.45) | NPC1RAB9ALMNA | |
| SCHEMBL2054773 | 0.68 | SLC6A9 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163956-B2 | Inhibitors of GLYT1 transporters | MERCK SHARP & DOHME CORP. (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163956-B2 | Inhibitors of GLYT1 transporters | MERCK SHARP & DOHME CORP. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20090286765-A1 | Therapeutic Agents | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2009-11-19 | — | — | US | disclosed |
| US-20090286765-A1 | Therapeutic Agents | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2009-11-19 | — | — | US | disclosed |
| WO-2006134341-A1 | THERAPEUTIC AGENTS | MERCK SHARP & DOHME LIMITED (GB) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286765-A1 | Therapeutic Agents | GRIA1, GRIN1, GLRA1 | KCNK3 1742/4885HDAC4 2091/4885HDAC6 1567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.